Pulmonary Cell News Volume 10.14 | Apr 15 2021

May 12, 2022

Pulmonary Cell News by STEMCELL Technologies

Vol. 10.14 – 15 April, 2021

TOP STORY

Therapeutic
Targeting of ATR Yields Durable Regressions in Small Cell Lung Cancers with High Replication Stress

Using chemical genetic screens, scientists identified inhibition of ataxia telangiectasia and rad3 related (ATR), the primary activator of the replication stress response, and topoisomerase I, nuclear enzyme that suppressed genomic instability, as synergistically cytotoxic in small cell lung cancer.
[Cancer Cell]

Abstract Graphical Abstract

Request your free copy of the 'Directed Differentiation of Pluripotent Stem Cells' Wallchart

PUBLICATIONSRanked by the impact factor of the journal

PD-L1
lncRNA Splice Isoform Promotes Lung Adenocarcinoma Progression via Enhancing C-Myc Activity

Employing qRT-PCR, Sanger sequencing, and RNA BaseScope analysis, scientists showed that human lung adenocarcinoma all produced a long non-coding RNA isoform of programmed death-ligand 1 (PD-L1) by alternative splicing, regardless if the tumor was positive or negative for the protein PD-L1.
[Genome Biology]

Full Article

LUNG CANCER

Epigenetic
Modulation of Immune Synaptic-Cytoskeletal Networks Potentiates γδ T Cell-Mediated Cytotoxicity in Lung Cancer

Scientists showed that DNA methyltransferase inhibitors upregulated surface molecules on lung cancer cells related to γδ T cell activation using quantitative surface proteomics.
[Nature Communications]

Full Article

SOD1
Regulates Ribosome Biogenesis in KRAS Mutant Non-Small Cell Lung Cancer

Researchers describe the generation of an inducible Cu/Zn-superoxide dismutase (Sod1) knockout in KRAS-driven non-small cell lung cancer mouse model.
[Nature Communications]

Full Article

SCAMP3
Is a Mutant EGFR Phosphorylation Target and a Tumor Suppressor in Lung Adenocarcinoma

Scientists used quantitative mass-spectrometry-based phosphoproteomics to identify secretory carrier membrane proteins (SCAMP3) as a target of mutant epidermal growth factor receptor in lung adenocarcinoma and further investigated the role of SCAMP3 in the regulation of lung tumorigenesis.
[Oncogene]

Abstract

Repression
of the AURKA-CXCL5 Axis Induces Autophagic Cell Death and Promotes Radiosensitivity in Non-Small-Cell Lung Cancer

Investigators showed that aurora inase A (AURKA) was upregulated in non-small-cell lung cancer (NSCLC) cell lines and tissues and that AURKA overexpression was significantly related to a poor prognosis, tumor stage and lymph node metastasis in NSCLC.
[Cancer Letters]

Abstract

HIF-1α
Promoted Vasculogenic Mimicry Formation in Lung Adenocarcinoma through NRP1 Upregulation in the Hypoxic Tumor Microenvironment

Researchers explored the role of the HIF-1α/NRP1 axis in mediating lung adenocarcinoma metastasis and vasculogenic mimicry (VM) formation.
[Cell Death & Disease]

Full Article

Identification
of a Targetable KRAS-Mutant Epithelial Population in Non-small Cell Lung Cancer

Scientists investigated the effects of in vivo PTC596 treatment, which affected BMI-1 activity, in murine model.
[Communications Biology]

Full Article

ON956-PneumaCult AOK Banner Ad-728x90-A.jpg

REVIEWS

Physiological
and Inflammatory Consequences of High and Low Respiratory Rate in Acute Respiratory Distress Syndrome

The authors present their point of view over the main experimental and clinical evidence available regarding the effect of respiratory rate on ventilator‐induced lung injury development.
[Acta Anaesthesiologica Scandinavica]

Abstract

INDUSTRY AND POLICY NEWS

EpiEndo Pharmaceuticals Announces Launch of First-in-Human Clinical Trial of a Non-Antibiotic Macrolide for the Treatment of Chronic Inflammatory Airway Diseases

EpiEndo Pharmaceuticals announced that the first subjects have been dosed in the Company’s first-in-human phase I clinical trial of its lead candidate, EP395, at the Medicines Evaluation Unit in Manchester, UK.
[EpiEndo Pharmaceuticals (businesswire)]

Press Release

Cyclica Teams Up with Top-Tier Academic Institutions to Identify a Repurposed Drug for COVID

Cyclica, in connection with leading Canadian research institutions, had predicted a drug, capmatinib, can be repurposed to attenuate the impact of coronavirus.
[Cyclica]

Press Release

FEATURED EVENT

Therapeutic
Targeting of ATR Yields Durable Regressions in Small Cell Lung Cancers with High Replication Stress

PD-L1
lncRNA Splice Isoform Promotes Lung Adenocarcinoma Progression via Enhancing C-Myc Activity

Epigenetic
Modulation of Immune Synaptic-Cytoskeletal Networks Potentiates γδ T Cell-Mediated Cytotoxicity in Lung Cancer

SOD1
Regulates Ribosome Biogenesis in KRAS Mutant Non-Small Cell Lung Cancer

SCAMP3
Is a Mutant EGFR Phosphorylation Target and a Tumor Suppressor in Lung Adenocarcinoma

Repression
of the AURKA-CXCL5 Axis Induces Autophagic Cell Death and Promotes Radiosensitivity in Non-Small-Cell Lung Cancer

HIF-1α
Promoted Vasculogenic Mimicry Formation in Lung Adenocarcinoma through NRP1 Upregulation in the Hypoxic Tumor Microenvironment

Identification
of a Targetable KRAS-Mutant Epithelial Population in Non-small Cell Lung Cancer

Physiological
and Inflammatory Consequences of High and Low Respiratory Rate in Acute Respiratory Distress Syndrome

EpiEndo Pharmaceuticals Announces Launch of First-in-Human Clinical Trial of a Non-Antibiotic Macrolide for the Treatment of Chronic Inflammatory Airway Diseases

Cyclica Teams Up with Top-Tier Academic Institutions to Identify a Repurposed Drug for COVID

World Stem Cell Summit

> See All Events

Postdoctoral Position: Lung stem cells and alveolar repair

Associate Professor – Xenotransplantation of the Lungs

Postdoctoral Research Fellow – Lung Carcinogenesis

Research Associate – Tissue Systems

Postdoctoral Fellow – Lung Injury/Repair

>
See All Jobs